Atrial fibrillation is more prevalent in men than women. Due to these sex differences in atrial fibrillation susceptibility, we examined whether sex hormones have differing associations with atrial fibrillation risk in men and women.
This analysis included 4883 (mean age = 63 ± 10 years; 39% women; 64% non-white) participants from the Multi-Ethnic Study of Atherosclerosis. Sex hormones (total testosterone, bioavailable testosterone, estradiol, and sex hormone binding globulin) were measured at baseline (2000-2002) for all male and all postmenopausal female participants. Atrial fibrillation was ascertained by hospital discharge records, Medicare claims data, and study electrocardiograms through December 31, 2012.
Over a median follow-up of 10.9 years, a total of 613 (13%) atrial fibrillation cases were detected. A higher incidence rate of atrial fibrillation was observed for males (n = 385, age-standardized incidence rate per 1000 person-years = 12.3, 95%CI = 11.1, 13.6) than females (n = 228, age-standardized incidence rate per 1000 person-years = 9.0, 95%CI = 7.9, 10.3). In men, higher bioavailable testosterone levels were associated with increased atrial fibrillation risk (HR = 1.32, 95%CI = 1.01, 1.74; p = 0.044; comparing 3rd to 1st tertile), while an association in the opposite direction was observed for women (HR = 0.81, 95%CI = 0.58, 1.13; p = 0.22; comparing 3rd to 1st tertile). Other hormones were not associated with atrial fibrillation in men or women.
Higher levels of endogenous bioavailable testosterone contribute to atrial fibrillation development in men. The combination of endogenous bioavailable testosterone and other risk factors potentially are important for atrial fibrillation development in men.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
A.S. Go, E.M. Hylek, K.A. Phillips, Y. Chang, L.E. Henault, J.V. Selby, D.E. Singer, Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and risk factors in Atrial fibrillation (ATRIA) study. JAMA 285(18), 2370–2375 (2001)
S.S. Chugh, R. Havmoeller, K. Narayanan, D. Singh, M. Rienstra, E.J. Benjamin, R.F. Gillum, Y.H. Kim, J.H. McAnulty Jr., Z.J. Zheng, M.H. Forouzanfar, M. Naghavi, G.A. Mensah, M. Ezzati, C.J. Murray, Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 129(8), 837–847 (2014)
R.B. Schnabel, X. Yin, P. Gona, M.G. Larson, A.S. Beiser, D.D. McManus, C. Newton-Cheh, S.A. Lubitz, J.W. Magnani, P.T. Ellinor, S. Seshadri, P.A. Wolf, R.S. Vasan, E.J. Benjamin, D. Levy, 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham heart study: a cohort study. Lancet 386(9989), 154–162 (2015)
D. Ko, F. Rahman, R.B. Schnabel, X. Yin, E.J. Benjamin, I.E. Christophersen, Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis. Nat. Rev. Cardiol. 13(6), 321–332 (2016)
E.Z. Soliman, M.M. Safford, P. Muntner, Y. Khodneva, F.Z. Dawood, N.A. Zakai, E.L. Thacker, S. Judd, V.J. Howard, G. Howard, D.M. Herrington, M. Cushman, Atrial fibrillation and the risk of myocardial infarction. JAMA Intern. Med. 174(1), 107–114 (2014)
W.T. O’Neal, K. Sangal, Z.M. Zhang, E.Z. Soliman, Atrial fibrillation and incident myocardial infarction in the elderly. Clin. Cardiol. 37(12), 750–755 (2014)
J.B. Olesen, C. Torp-Pedersen, M.L. Hansen, G.Y. Lip, The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb. Haemost. 107(6), 1172–1179 (2012)
E.J. Benjamin, P.A. Wolf, R.B. D’Agostino, H. Silbershatz, W.B. Kannel, D. Levy, Impact of atrial fibrillation on the risk of death: the framingham heart study. Circulation 98(10), 946–952 (1998)
J. Friberg, H. Scharling, N. Gadsboll, T. Truelsen, G.B. Jensen; Copenhagen City Heart, S., Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study). Am. J. Cardiol. 94(7), 889–894 (2004)
M.L. Mongraw-Chaffin, C.A. Anderson, M.A. Allison, P. Ouyang, M. Szklo, D. Vaidya, M. Woodward, S.H. Golden, Association between sex hormones and adiposity: qualitative differences in women and men in the multi-ethnic study of atherosclerosis. J. Clin. Endocrinol. Metab. 100(4), E596–600 (2015)
L. Wang, M. Szklo, A.R. Folsom, N.R. Cook, S.M. Gapstur, P. Ouyang, Endogenous sex hormones, blood pressure change, and risk of hypertension in postmenopausal women: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 224(1), 228–234 (2012)
R.R. Kalyani, M. Franco, A.S. Dobs, P. Ouyang, D. Vaidya, A. Bertoni, S.M. Gapstur, S.H. Golden, The association of endogenous sex hormones, adiposity, and insulin resistance with incident diabetes in postmenopausal women. J. Clin. Endocrinol. Metab. 94(11), 4127–4135 (2009)
J.W. Magnani, C.B. Moser, J.M. Murabito, L.M. Sullivan, N. Wang, P.T. Ellinor, R.S. Vasan, E.J. Benjamin, A.D. Coviello, Association of sex hormones, aging, and atrial fibrillation in men: the Framingham Heart Study. Circ. Arrhythm. Electrophysiol. 7(2), 307–312 (2014)
D.E. Bild, D.A. Bluemke, G.L. Burke, R. Detrano, A.V. Diez Roux, A.R. Folsom, P. Greenland, D.R. Jacob Jr., R. Kronmal, K. Liu, J.C. Nelson, D. O’Leary, M.F. Saad, S. Shea, M. Szklo, R.P. Tracy, Multi-ethnic study of atherosclerosis: objectives and design. Am. J. Epidemiol. 156(9), 871–881 (2002)
R.B. Devereux, P.N. Casale, R.R. Eisenberg, D.H. Miller, P. Kligfield, Electrocardiographic detection of left ventricular hypertrophy using echocardiographic determination of left ventricular mass as the reference standard. Comparison of standard criteria, computer diagnosis and physician interpretation. J. Am. Coll. Cardiol. 3(1), 82–87 (1984)
S.H. Golden, A.S. Dobs, D. Vaidya, M. Szklo, S. Gapstur, P. Kopp, K. Liu, P. Ouyang, Endogenous sex hormones and glucose tolerance status in postmenopausal women. J. Clin. Endocrinol. Metab. 92(4), 1289–1295 (2007)
T. Naessen, U. Sjogren, J. Bergquist, M. Larsson, L. Lind, M.M. Kushnir, Endogenous steroids measured by high-specificity liquid chromatography-tandem mass spectrometry and prevalent cardiovascular disease in 70-year-old men and women. J. Clin. Endocrinol. Metab. 95(4), 1889–1897 (2010)
M.A. Rosenberg, K.K. Patton, N. Sotoodehnia, M.G. Karas, J.R. Kizer, P.J. Zimetbaum, J.D. Chang, D. Siscovick, J.S. Gottdiener, R.A. Kronmal, S.R. Heckbert, K.J. Mukamal, The impact of height on the risk of atrial fibrillation: the cardiovascular health study. Eur. Heart J. 33(21), 2709–2717 (2012)
D.D. McManus, V. Xanthakis, L.M. Sullivan, J. Zachariah, J. Aragam, M.G. Larson, E.J. Benjamin, R.S. Vasan, Longitudinal tracking of left atrial diameter over the adult life course: clinical correlates in the community. Circulation 121(5), 667–674 (2010)
W.T. O’Neal, Z.M. Zhang, L.R. Loehr, L.Y. Chen, A. Alonso, E.Z. Soliman, Electrocardiographic advanced interatrial block and atrial fibrillation risk in the general population. Am. J. Cardiol. 117(11), 1755–1759 (2016)
E.Z. Soliman, A. Alonso, J.R. Misialek, A. Jain, K.E. Watson, D.M. Lloyd-Jones, J. Lima, S. Shea, G.L. Burke, S.R. Heckbert, Reference ranges of PR duration and P-wave indices in individuals free of cardiovascular disease: the multi-ethnic study of atherosclerosis (MESA). J. Electrocardiol. 46(6), 702–706 (2013)
A. Alonso, S.K. Agarwal, E.Z. Soliman, M. Ambrose, A.M. Chamberlain, R.J. Prineas, A.R. Folsom, Incidence of atrial fibrillation in whites and African-Americans: the atherosclerosis risk in communities (ARIC) study. Am. Heart J. 158(1), 111–117 (2009)
The authors thank the other investigators, the staff, and the participants of the MESA study for their valuable contributions. A full list of participating MESA investigators and institutions can be found at http://www.mesa-nhlbi.org.
This research was supported by contracts N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, and N01-HC-95169 from the National Heart, Lung, and Blood Institute. This research was supported by grants UL1-TR-000040 and UL1-TR-001079 from the National Center for Research Resources, 16EIA26410001 from the American Heart Association, and R01-HL-127659 from the National Heart, Lung, and Blood Institute. W.T.O. is supported by the National Heart, Lung, And Blood Institute of the National Institutes of Health under Award Number F32-HL-134290. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Conflict of interest
Dr. Nazarian is principal investigator for research funds awarded to Johns Hopkins University from Biosense Webster Inc and is also a consultant to Biosense Webster, St Jude Medical, CardioSolv, and Spectranetics. The other authors declare that they have no competing interests.
All procedures in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Electronic supplementary material
About this article
Cite this article
O’Neal, W.T., Nazarian, S., Alonso, A. et al. Sex hormones and the risk of atrial fibrillation: The Multi-Ethnic Study of Atherosclerosis (MESA). Endocrine 58, 91–96 (2017). https://doi.org/10.1007/s12020-017-1385-3
- Sex hormones
- Atrial fibrillation